(AAT)n repeat in the cannabinoid receptor gene, CNR1: association with schizophrenia in a Spanish population

Eur Arch Psychiatry Clin Neurosci. 2006 Oct;256(7):437-41. doi: 10.1007/s00406-006-0665-3. Epub 2006 Jun 20.

Abstract

The cannabinoid receptor 1 gene (CNR1) has been associated with addictive disorders and schizophrenia in different studies. We have compared the frequencies of the alleles for the 3'-UTR CNR1 microsatellite in a sample of 113 Spanish schizophrenic patients, including 68 with comorbid substance abuse, and 111 healthy controls. We report that the frequency of the allele 4 of this microsatellite is significantly lower in schizophrenia patients when compared with controls (chi(2) = 7.858; df 1; P = 0.005). No differences have been found with respect to substance abuse.Thus, the allele 4 represents, in our sample, a protective factor against schizophrenia (odds ratio 0.468, 95% confidence interval (CI) 0.27-0.79). The population attributable genetic risk for the allele 4 absence is 30% (95% CI = 17-41%) and the attributable risk for the allele 4 absence in those with schizophrenia is 53% (95% CI = 20-73%). Our results suggest that, independent of substance abuse, differences in the cannabinoid system function could be involved in the vulnerability to schizophrenia in Spanish population.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Alleles
  • Female
  • Gene Frequency
  • Genotype
  • Humans
  • Male
  • Microsatellite Repeats / genetics
  • Odds Ratio
  • Psychiatric Status Rating Scales
  • Receptor, Cannabinoid, CB1 / genetics*
  • Reverse Transcriptase Polymerase Chain Reaction
  • Risk
  • Schizophrenia / epidemiology
  • Schizophrenia / genetics*
  • Spain / epidemiology
  • Trinucleotide Repeats / genetics

Substances

  • Receptor, Cannabinoid, CB1